GlaxoSmithKline Pharmaceuticals Ltd banner

GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO

Watchlist Manager
GlaxoSmithKline Pharmaceuticals Ltd Logo
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Watchlist
Price: 2 457 INR 1.54% Market Closed
Market Cap: ₹416.2B

GlaxoSmithKline Pharmaceuticals Ltd
Total Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

GlaxoSmithKline Pharmaceuticals Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Total Equity
₹17.1B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Equity
₹360.1B
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Equity
₹329.2B
CAGR 3-Years
15%
CAGR 5-Years
14%
CAGR 10-Years
11%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Equity
₹778.2B
CAGR 3-Years
14%
CAGR 5-Years
12%
CAGR 10-Years
11%
Lupin Ltd
NSE:LUPIN
Total Equity
₹196.3B
CAGR 3-Years
18%
CAGR 5-Years
9%
CAGR 10-Years
7%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Equity
₹84.5B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
10%
No Stocks Found

GlaxoSmithKline Pharmaceuticals Ltd
Glance View

Market Cap
416.2B INR
Industry
Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Ltd., a subsidiary of the global healthcare juggernaut GSK, stands as a pillar in the pharmaceutical industry, with roots deeply entrenched in innovation and a robust pipeline of healthcare products. This company weaves a narrative of relentless pursuit in the creation and distribution of a wide variety of medicines and vaccines, aimed at improving the quality of human life. Operating predominantly in the areas of pharmaceuticals, vaccines, and consumer healthcare, GSK integrates cutting-edge research with strategic collaborations. This enables them to address pressing medical needs, such as respiratory diseases, HIV, infectious diseases, and oncology, amongst others, thereby leveraging their expertise to cater to diverse healthcare demands. The heart of their revenue generation lies in the seamless amalgamation of research acumen and market presence. By investing significantly in research and development, GSK continually introduces groundbreaking therapies and health solutions. The company has adeptly structured its operations to create a strong global presence, which not only involves selling directly to healthcare providers and governments but also innovating its supply chain to maximize reach. Moreover, GSK's astute marketing efforts ensure that their products are not just effective but also attuned to consumer needs. With a focus on sustainable growth and transformative medicines, GSK’s story becomes a testament to how science-driven strategies can forge pathways to a healthier world while simultaneously fueling the company’s economic engine.

GLAXO Intrinsic Value
1 376.65 INR
Overvaluation 44%
Intrinsic Value
Price ₹2 457

See Also

What is GlaxoSmithKline Pharmaceuticals Ltd's Total Equity?
Total Equity
17.1B INR

Based on the financial report for Dec 31, 2025, GlaxoSmithKline Pharmaceuticals Ltd's Total Equity amounts to 17.1B INR.

What is GlaxoSmithKline Pharmaceuticals Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
5%

Over the last year, the Total Equity growth was 2%. The average annual Total Equity growth rates for GlaxoSmithKline Pharmaceuticals Ltd have been 5% over the past three years , 5% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett